Corixa (CRXA) - infos

Hat einer von euch Hintergrundinfos zu CRXA. Haben vor kurzem extrem gute Zahlen veröffentlicht. Eine wirkliche Kursreaktion steht aber noch aus. Chart kann in ein Dreieck laufen...

chart.bigcharts.com/bc3/intchart/frames/...203&mocktick=1" style="max-width:560px" border=0>

www.finanznachrichten.de/...hten-aktien/corixa-corporation.asp

ich wundere mich warum die aktie kaum reagiert. news sind gut und die zahlen waren der hammer?

chart.bigcharts.com/bc3/intchart/frames/...nd=6625&mocktick=1" style="max-width:560px" >
Bexxar ist schliesslich ein von der FDA approved Krebsmittel gegen Lymphknoten und das verspricht steigende Umsätze,der Chart deutet daraufhin,dass die die Stochastik steigen wird,MACD geht in den positiven Bereich...

Bexxar will be sold to patients whose disease relapsed after chemotherapy and didn't respond to Genetech Inc. (DNA) and IDEC Pharmaceuticals Inc.'s (IDPH) Rituxan, a drug that's become the standard treatment in NHL. It will compete directly with IDEC's Zevalin, a drug launched last April with sales that have disappointed analysts.

Zevalin only contributed $5.7 million to IDEC's first quarter earnings.

Corixa spokesman Jim DeNike said the company's 2003 guidance has previously included a mid-year launch of Bexxar and that hasn't changed. The company continues to expect revenue of $50 million to $60 million this year with a net operating cash burn of $50 million to $70 million, he said.

At the end of the first quarter, the company had $101.1 million in cash. Since then the company established a $75 million equity line of credit from BNY Capital Markets and just recently raised $130 million through a combined pipe transaction involving a private placement and a convertible offering.

DeNike said Corixa and Glaxo haven't determined a final price for Bexxar yet, but said that it will be comparable to other similar therapies.

IDEC's Zevalin costs about $28,000 per course of therapy, Banc of America analyst Mike King said.

King, who covers IDEC, not Corixa, said that Bexxar approval came a little earlier than he was expecting, keeping with the current trend of quick approvals at the FDA. But he doesn't think it will have a big impact on IDEC.

"It's a tough market," he said. "The drugs are complicated. Reimbursement is still cloudy. Look at the problems that IDPH is having selling Zevalin."  

Corixa and GlaxoSmithKline Inc. (GSK) in Canada entered into an agreement in May 2003 whereby in the event of product approval GSK will market BEXXAR in Canada. Under the terms of the agreement, GSK is responsible for registration, marketing and sales of the product in Canada. Corixa is responsible for the manufacture and supply of BEXXAR therapy to GSK for the Canadian market.

About BEXXAR

On July 31, 2003, Corixa and GSK announced that they have begun sales and marketing of BEXXAR to cancer treatment centers, oncologists and nuclear medicine professionals in the United States. The BEXXAR therapeutic regimen, which is given in four office visits over one to two weeks, culminating in the administration of a patient-specific therapeutic dose, is indicated in the United States for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma (NHL), with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.

About Corixa

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials.

The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Montana, and South San Francisco. For more information, visit Corixa's Web site at www.corixa.com.

Corixa Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the prospects for approval of our product, BEXXAR(TM) therapy by Health Canada, statements about our potential future royalties from the marketing agreement with GSK and other statements about our plans, objectives, intentions and expectations. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa's actual results include, but are not limited to, the risk that we do not obtain approval for the sale of BEXXAR(TM) therapy in Canada, the risk that we do not receive the expected royalties from our agreement with GSK and the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2003, copies of which are available from our investor relations department. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

BEXXAR(TM) is a trademark of Corixa Corporation, used under license by GlaxoSmithKline Inc.

(BEXXAR® is a registered trademark in the United States.)

einziger wehrmutstropfen ist zur zeit das volumen aber bin für nächste woche optimistisch.ichart.yahoo.com/...amp;p=s&t=2y&l=on&z=l&q=l" style="max-width:560px" border=0>

Splits: none

 

"We are pleased to announce continued product commercialization progress with the approval of SUPERVAX containing our RC-529 adjuvant," said Steven Gillis, Ph.D., chairman and chief executive officer at Corixa. "This milestone -- soon after the filing for approval of GlaxoSmithKline's Fendrix containing Corixa's MPL adjuvant -- is further evidence of our strong commitment to aggressively move more products through clinical testing and on to product approval. The strength of our adjuvant technology and its potential contribution to Corixa's future product sales and royalty income is a distinguishing characteristic of our vaccine development efforts."

About Corixa's Adjuvant Business

Corixa's adjuvant technology is based on the knowledge that certain microbial products long have been recognized as potent immune system regulators and have been shown to induce a broad range of known cytokines, a class of substances that are produced by cells of the immune system and can affect the immune response. Modifications of these microbial products and their physical and biological delivery to the immune system can influence the way cytokines are expressed, as well as the recipient's own physiological responses. Such responses mimic the normal, protective responses that are initiated during microbial infection or injury.

With its partners, Corixa is evaluating its adjuvants in adult and pediatric vaccines that are designed to be safe and more effective in protecting against a broad range of diseases.

In addition to RC-529 adjuvant, Corixa's adjuvant portfolio also includes MPL, a derivative of the lipid A molecule found in gram-negative bacteria, one of the most potent immune system stimulants. Corixa also owns patented technology for extracting MPL adjuvant from bacterial cell walls. Several of Corixa's partners are evaluating MPL adjuvant in vaccines for development in allergy, cancer and infectious disease targets. MPL adjuvant has been administered to more than 12,000 patients in more than 33,000 doses as a vaccine adjuvant.

About Corixa

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. On June 30, 2003, Corixa announced that the FDA approved BEXXAR® for the treatment of patients with CD20 positive, follicular, NHL, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.

Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. In addition to BEXXAR, Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco. For more information, please visit Corixa's Web site at www.corixa.com/.

Corixa Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the commercialization of our RC-529 adjuvant, statements regarding potential future sales and royalty income from our adjuvant technology and other statements about our plans, objectives, intentions and expectations. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa's actual results include, but are not limited to, the risk that we are unable to commercialize our RC-529 adjuvant or other products incorporating our adjuvant technology, the risk that royalties from our RC-529 adjuvant do not grow as we expect or that we do not achieve the royalty income from future products incorporating our adjuvant technology that we expect and the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2003, copies of which are available from our investor relations department. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.